BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a significant increase in short interest in July. As of July 15th, there was short interest totalling 21,810,000 shares, an increase of 22.0% from the June 30th total of 17,880,000 shares. Based on an average daily volume of 3,620,000 shares, the days-to-cover ratio is presently 6.0 days.

Insider Transactions at BioCryst Pharmaceuticals

In other news, Director Steven K. Galson purchased 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were bought at an average cost of $5.49 per share, with a total value of $120,450.60. Following the completion of the transaction, the director now directly owns 51,551 shares in the company, valued at approximately $283,014.99. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Steven K. Galson purchased 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were bought at an average cost of $5.49 per share, with a total value of $120,450.60. Following the completion of the transaction, the director now directly owns 51,551 shares in the company, valued at approximately $283,014.99. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Anthony Doyle acquired 36,300 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the completion of the transaction, the chief financial officer now directly owns 266,744 shares in the company, valued at approximately $1,485,764.08. The disclosure for this purchase can be found here. Insiders have bought a total of 103,601 shares of company stock valued at $596,338 over the last three months. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after acquiring an additional 2,371,401 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 13.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after purchasing an additional 1,500,000 shares during the last quarter. Kynam Capital Management LP lifted its stake in BioCryst Pharmaceuticals by 41.9% in the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after purchasing an additional 1,927,491 shares during the last quarter. Braidwell LP lifted its stake in BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after purchasing an additional 355,497 shares during the last quarter. Finally, Norges Bank bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $13,278,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 0.9 %

Shares of BCRX stock traded down $0.07 on Tuesday, reaching $7.45. The stock had a trading volume of 1,210,394 shares, compared to its average volume of 3,395,134. The firm’s 50-day moving average is $6.62 and its two-hundred day moving average is $5.74. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $7.93.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. The firm had revenue of $92.80 million for the quarter, compared to analyst estimates of $85.62 million. The business’s revenue was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.28) EPS. Sell-side analysts predict that BioCryst Pharmaceuticals will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BCRX shares. JMP Securities upped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.